- $52.03m
- -$68.16m
- 20
- 50
- 18
- 18
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.44 | ||
| Price to Tang. Book | 0.44 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -72.84% | ||
| Return on Equity | -79.26% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PepGen Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases. The Company’s pipeline consists of two clinical stage programs: PGN-EDO51 for duchenne muscular dystrophy (DMD) patients who are amenable to exon 51-skipping and PGN-EDODM1 for myotonic dystrophy type 1 (DM1) patients. It also has three additional preclinical stage programs: PGN-EDO53, PGN-EDO45 and PGN-EDO44.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 9th, 2020
- Public Since
- May 6th, 2022
- No. of Shareholders
- 11
- No. of Employees
- 81
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 32,720,943
- Address
- 245 Main St, 2nd Floor, CAMBRIDGE, 02142
- Web
- https://pepgen.com
- Phone
- +1 7034568000
- Auditors
- KPMG LLP
Upcoming Events for PEPG
PepGen Inc Annual Shareholders Meeting
Q2 2025 PepGen Inc Earnings Release
Similar to PEPG
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the PepGen share price?
As of Today at 22:37 UTC, shares in PepGen are trading at $1.59. This share price information is delayed by 15 minutes.
How has the PepGen share price performed this year?
Shares in PepGen last closed at $1.59 and the price had moved by -89.03% over the past 365 days. In terms of relative price strength the PepGen share price has underperformed the S&P500 Index by -90.11% over the past year.
What are the analyst and broker recommendations for PepGen?
The overall consensus recommendation for PepGen is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the PepGen dividend yield?
PepGen does not currently pay a dividend.
Does PepGen pay a dividend?
PepGen does not currently pay a dividend.
When does PepGen next pay dividends?
PepGen does not currently pay a dividend.
How do I buy PepGen shares?
To buy shares in PepGen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of PepGen?
As of the previous close price of $1.59, shares in PepGen had a market capitalisation of $52.03m.
Where are PepGen shares listed?
Here are the trading details for PepGen:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: PEPG
What kind of share is PepGen?
Based on an overall assessment of its quality, value and momentum PepGen is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a PepGen share price forecast for 2025?
The analyst consensus target price for shares in PepGen is $12.20. That is 667.3% above the last closing price of $1.59.
Analysts covering PepGen currently have a consensus Earnings Per Share (EPS) forecast of -$2.67 for the next financial year.
Find out moreWhat is the trend in the PepGen share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like PepGen. Over the past six months, its share price has underperformed the S&P500 Index by -75.35%.
As of the last closing price of $1.59, shares in PepGen were trading -71.7% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the PepGen PE Ratio?
The PepGen PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.59.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of PepGen?
We do not have data on PepGen's directors